论文部分内容阅读
应用α-IFN治疗毛细胞白血病(HCL)患者23人(男18、女5,年龄36～78岁),其中6人脾已切除,15人均有脾肿大。由Well-come公司提供的部分纯化的α-IFN是从人淋巴母细胞系获得的。病人每天自行肌注α-IFN30单位。治疗4周后,若外周血象没有改善,则增至60单位。疗效分为三类:(1)完全缓解(CR):骨髓和外周血毛细胞(HG)消失,肿大的脾脏及各项血液指标恢复正常;(2)稳定的部分缓解(PR):骨髓和外周血的HC由原来的多于50%,至少在一个月内消失;(3)轻微缓解(MR):外周血的HC至少有一次消失。介于CR和PR中的病人,α-IFN可减至每周三次,维持治疗3个月或更长时间。在10～27个月内对绝大多数病人进行追踪发现:7人为CR,11人为PR,5人为MR
Twenty-three patients (18 males and 5 females aged 36-78 years) with α-IFN were treated for hair cell leukemia (HCL), of whom 6 had splenectomy and 15 had splenomegaly. Partially purified alpha-IFN provided by Well-Come Company was obtained from the human lymphoblastoid cell line. Patients daily intramuscular injection of α-IFN30 units. After 4 weeks of treatment, if peripheral blood does not improve, increase to 60 units. The efficacy was divided into three categories: (1) complete remission (CR): bone marrow and peripheral blood cells (HG) disappeared, the enlarged spleen and various blood parameters returned to normal; (2) stable partial response And peripheral blood HC from the original more than 50%, at least within a month disappeared; (3) mild relief (MR): peripheral blood HC disappeared at least once. In patients with CR and PR, alpha-IFN may be reduced to three times a week for 3 months or longer. The majority of patients were followed up within 10-27 months: 7 for CR, 11 for PR, and 5 for MR